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Genetic studies in the last 5 years have greatly facilitated our understanding of how the dysregulation of diverse components of
the innate immune system contributes to pathophysiology of SLE. A role for macrophages in the pathogenesis of SLE was first
proposed as early as the 1980s following the discovery that SLE macrophages were defective in their ability to clear apoptotic cell
debris, thus prolonging exposure of potential autoantigens to the adaptive immune response. More recently, there is an emerging
appreciation of the contribution both monocytes and macrophages play in orchestrating immune responses with perturbations
in their activation or regulation leading to immune dysregulation. This paper will focus on understanding the relevance of genes
identified as being associated with innate immune function of monocytes and macrophages and development of SLE, particularly
with respect to their role in (1) immune complex (IC) recognition and clearance, (2) nucleic acid recognition via toll-like receptors
(TLRs) and downstream signalling, and (3) interferon signalling. Particular attention will be paid to the functional consequences
these genetic associations have for disease susceptibility or pathogenesis.
1. Macrophages in Disease: SLE Candidate
Genes and Functional Relevance
Systemic lupus erythematosus (SLE) is amultisystem chronic
autoimmune disease, which affects approximately 0.1% of
the population, with women being approximately nine times
more likely to develop the disease than men [1]. SLE
is a complex disease encompassing a broad spectrum of
clinical symptoms, particular combinations of which can
result in varying disease severity. To date the majority
of work undertaken with respect to understanding the
pathophysiology of this condition has focused on the
autoreactive B and T lymphocytes [2]. However, recently
attention has shifted to the role of the innate immune system
and particularly myeloid cells in disease. Both monocytes
and macrophages are phenotypically altered in SLE, with
SLE macrophages demonstrated to have reduced uptake of
apoptotic cells, enhanced activatory status, an altered skew
of proinflammatory and anti-inflammatory macrophages
and an overproduction of inflammatory cytokines such as
tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-
6), interleukin-10 (IL-10), and antiviral type I interferons
(IFNs) (Figure 1) [3–5]. As such, SLE monocytes and
macrophages present self-antigens to autoreactive T cells
in an inflammatory context, rather than the immuno-
silent presentation normally associated with material from
apoptotic cells [3]. In addition to this, the overproduction of
type I IFNs by myeloid cells (including dendritic cells) also
contributes to the breaking of immune tolerance due to their
ability to stimulate antibody production and class switching
from B cells [4]. The inadequate regulation of these processes
in myeloid cells may be as a result of the influence of variants
within SLE susceptibility genes.
Genetic analysis in human and murine studies indicate
that susceptibility to SLE is heritable and that a number of
different genetic loci are associated with disease risk [5]. Both
candidate gene studies and Genome-wide association studies
(GWAS) have unearthed many genes whose function can
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Figure 1: Dysregulation of macrophage function in SLE. The ability of the immune system to regulate macrophage function is altered in
patients suffering from SLE. SLE macrophages have a defect in apoptotic cell clearance, overproduce IL-21, IFNs, IL-10, IL-6, and NO, have
enhanced antigen presentation capacity and are primed for activation, leading to a skew towards autoimmunity.
be clustered into 3 different categories, each clearly rooted
in innate immune cell signalling and function (Table 1): (1)
immune complex (IC) recognition and clearance such as the
complement components and the Fc gamma receptors [6–
8]; (2) nucleic acid recognition via toll-like receptors (TLRs)
[9–11] and downstream signalling components such as TNF
receptor-associated factor-6 (TRAF6) [12] and interferon
regulatory factors (IRFs) [13] and (3) interferon signalling
[14]. Characterisation of the molecular involvement of many
of these genes in the function of SLE monocytes and
macrophages has placed these cells as key orchestrators
of SLE pathogenesis. Whilst the focus of this paper is
the involvement of these candidate genes in macrophage
function and their contribution to SLE pathology, it must be
stressed that many of the candidate genes discussed below,
particularly those that regulate type I IFN production, also
play an important role in dendritic cell-driven autoimmune
pathology [15, 16].
2. Immune Complex Recognition and Uptake
2.1. The Complement System and Its Association with SLE.
The principal function of activated components of the
complement system include production of inflammatory
and chemotactic proteins (C3a and C5a), cell lysis through
the formation of the membrane attack complex (complex of
C5b-9 proteins), andmost importantly in the context of SLE,
recognition and clearance of immune complexes and apop-
totic cells (C1–C4) [6–8, 44]. Although genetic deficiencies
in individual loci are rare, homozygous deficiency of each of
the classical pathway components (C1q, C1r, C1s, C4, and
C2) has been shown to be associated with SLE in humans
[22]. A hierarchy of susceptibility and severity of disease is
present where association is greatest with homozygous C1q
deficiency followed by homozygous C4 and C2 deficiency
[8]. Hereditary deficiencies of C1s and C1r are rarer than that
of C1q and, in themajority of cases, deficiencies of both these
components are inherited together [19, 20]. Both C1q and
C4 are important in clearance of apoptotic cells and immune
complexes, thereby preventing inappropriate activation of
autoreactive B and T cells. Thus, reduced functioning of this
important housekeeping function of complement proteins
is strongly associated with increased risk of developing SLE
[13–15, 19, 45].
C1q functions in facilitating clearance of immune com-
plexes and apoptotic cells, thus protecting against autoim-
munity. In addition, recent work has demonstrated that
C1q can protect against SLE by preventing the production
of type I IFN by dendritic cells [45, 46]. Individuals with
a congenital deficiency of C1q gene (C1qD) develop SLE-
like symptoms at more than 90% prevalence [47, 48].
Interestingly, the importance of ethnicity and the possible
influence of haplotypes is highlighted by the observation that
although C1q deficiency has been reported in Turkish [17]
and Mexican [18] individuals affected by SLE, no association
has been in Malaysian patients [49].
Homozygous deficiency of complement C4 is one of the
strongest genetic risk factors for SLE and results in lupus-like
disease in approximately 80% of the 28 known affected indi-
viduals [23, 24, 47]. To date, 28 individuals with complete
C4 deficiency from 19 families have been reported, among
these 15 individuals developed SLE, 7 developed lupus-like
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Table 1: Polymorphisms of genes associated with SLE outlined in this review.
Category Gene SNP Ethnicity
Immune complex recognition
C1q [8, 17, 18]
C1r [19]
C1s [20] Rs292001 [21] Turkish [17], Mexican [18]
C2 [22]
C4 [8, 22–24]
Nucleic acid recognition
rs3853839 [25] Chinese, Japanese [25]
rs179019 [26] Japanese [26]
TLR7 [25] rs179010 [26]
rs179008 [27] Brazilian [27]
rs5743836 [27] Brazilian [27]
TLR9 rs352139 [28] Japanese [28]
rs352140 [29] Chinese [29]
Asian [30],
IRF7 rs1131665 [30] European American [30],
African American [30]
rs5030437 [12]
TRAF6 rs4755453 [12] African American [12]
rs540386 [12]
rs13192841 [31] European [31]
rs2230926 [31, 32] European [31],
TNFAIP3 rs6922466 [31] Chinese Han [33]
rs5029939 [34] European [31]
rs7708392 [35, 36] Caucasian, Chinese [35, 36]
TNIP1 rs10036748 [35, 36]
Japanese [26]
Caucasian,Chinese [35, 36]
Interferon signalling
rs7582694 [37] Caucasian [37]
STAT4
rs7601754 [38] Caucasian [38]
rs7574865 [38] Caucasian [38],
Northern Han Chinese [39]
rs7582694 [40] Caucasian [40]
TYK2 rs280519 [41] UK, Swedish [41]
rs2304256 [13] Scandinavian [13]
IRF5
rs12720270 [42] UK [42]
rs10488631 [43]
disease and four of the remaining subjects had kidney disease
[24]. Through a five nucleotide substitution in exon 26, the
C4 gene can encode either a C4A or a C4B protein [50], both
of which have differential functions. C4A preferentially binds
to amino groups in immune complexes and is the preferential
ligand for complement receptor 1 (CR1) [51] whereas C4B
is thought to be a more potent initiator of the complement
activation cascade. The complement C4 gene located in the
class III region of the major histocompatibility complex
(MHC) on chromosome 6p21.3 and exhibits significant
interindividual copy number variation (CNV). Boteva et al.
demonstrated low C4A genome copy number significantly
predisposed to SLE in UK and Spanish populations (P <
0.001) however, high C4A genome copy number was not
associated with disease in either case (P = 0.63 and P =
0.76, resp.) [52]. Interestingly, C4B genome copy number
demonstrated no association in the UK SLE group but
was significantly associated with the Spanish cohort (P =
0.001). The discrepancies reported across different patient
populations with respect to C4 copy number suggests that
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partial C4 deficiency states secondary to low C4A or C4B
copy number are not independent genetic risk factors for
susceptibility to disease [52, 53].
In addition to the rare inherited immunodeficiencies
observed, many SLE patients have reduced levels of circu-
lating C1q or C4 as a result of autoantibodies against these
proteins, thus resulting in loss of their protective functions.
Thus combined, mutations or decreased function of the
early complement components has a profound effect on an
individual’s susceptibility to developing SLE.
2.2. Fc Gamma Receptors. Studies have investigated the
contribution of the Fc-gamma family of receptors (FcγRs) to
the pathogenesis of SLE given their role in the recognition of
the Fc portion of IgG and subsequent responses to circulating
and deposited immune complexes. Recent work in animal
models indicates that the development of many human
autoimmune diseases might be caused by impairment of the
FcγR regulatory system (reviewed in [54]). FcγRs bind IgG,
and can be further classified as activatory (FcγRI, IIA, IIIA,
IIIB, and IV) or inhibitory (FcγRIIB) following IgG binding
[55]. Additionally they can be subcategorised by relative
affinity for IgG, with FcγRI having highest affinity, while
FcγRII and III display lower affinity [56]. Currently there
are no known polymorphisms in the FcγRI gene reported
in humans and the rare individuals lacking this gene are
healthy with no signs of autoimmune immune pathology
[57]. However, polymorphisms in the activatory receptors
FcγRIIA and FcγRIIIA have been identified [58–64].
FcγRII and III are encoded by two families of genes
(FCGR2, FCGR3) clustered on chromosome 1q23-24, each
containing multiple distinct genes [58]. FcγRIIA is a low-
affinity receptor, comprised of multiple isoforms, which is
expressed by B cells, monocytes, macrophages, and dendritic
cells (DCs). It has two codominantly expressed alleles,
R131 and H131, which differ in their affinity for IgG
subclasses. Substitition of arginine to histidine at position
131 at the membrane proximal portion of the receptor
results in enhanced affinity of FcγRIIA for binding of IgG2
and IgG3 by the H131 variant and increased levels of
phagocytosis [59]. The allelic variant of FcγRIIA (R131) has
been found to be strongly associated with lupus nephritis
and renal failure in Brazilian lupus patients (P = 0.06) [60].
Interestingly meta analysis of European, African, and Asian
populations demonstrated a significant association between
the homozygous RR genotype and the development of SLE
(P = 0.0016). This polymorphism was shown to increase
the risk of devolving SLE 1.3-fold [61]. However analysis
of this polymorphism in a Malaysian population found no
significant association with disease [62].
FcγRIII encodes an activatory FcγRwhich is expressed on
NK cells andmonocytes, and has two isoforms: FcγRIIIA and
FcγRIIIB. The wild-type sequence at position 176 encodes
a phenylalanine (176-F) while the polymorphic variant is
176-valine (176-V) resulting in increased binding of IgG1
and IgG3 [63]. Recent studies in Japanese and Chinese
patient cohorts found that positivity for the 176F allele was
significantly increased in patients (P = 0.02 and P = 0.05
resp.), indicating a significant association of this allele with
SLE [64, 65]. Additionally a significant association with this
polymorphism and the development of lupus nephritis was
observed among the Japanese patient cohort (P = 0.03) [64].
FcγRIIIB is an alternative membrane form of FcγRIII
that is predominantly expressed on neutrophils and pref-
erentially binds IgG1 and IgG3. The FcγRIIIB gene has
three polymorphic forms known as HNA-1a, HNA-1b, and
HNA-1c, encoded by the alleles FCGR3B∗01, FCGR3B∗02,
and FCGR3B ∗03 (also referred to NA1, NA2, and SH)
[66]. These different isoforms of FcγRIII exhibit differential
function with increased levels of phagocytosis reported
for FCGR3B∗01 homozygotes compared to cells from
FCGR3B∗02 homozygotes, despite similar levels of receptor
expression [67]. Reduced function of the FCGR3B∗02 allele
has been associated with impaired IC clearance in Caucasian
populations [68] and has been strongly associated with
disease susceptibility in Japanese and Thai populations (P =
0.008 and P = 0.02, resp.) [69, 70] and significantly
associated with the development of lupus nephritis among
the Japanese patient cohort (P = 0.007), whereas as no
association was found in other population studies [62, 71].
As an inhibitory FcγR, loss of FcγRIIB not surprisingly
results in development of lupus-like symptoms in mice,
with the development of autoantibodies and autoimmune
glomerulonephritis, consistent with a lack of inhibitory
mechanisms on the development of autoreactive B cells [72].
Subsequent studies have demonstrated that increasing the
expression of FcγRIIB in B cells derived from autoimmune-
prone mice restored tolerance and prevented autoimmune
disease [73]. With respect to the role of FcγRIIB in human
autoimmune disease, reduced expression of FcγRIIb has
been reported for memory B cells and plasma cells from
SLE patients [74]. Interestingly, a polymorphism of FcγRIIb
which changes the threonine at position 232 to an isoleucine
(I232T) was found to be associated with SLE as positivity
for the 232I allele was significantly decreased in SLE patients
suggesting a significant association of the 232T/T genotype
with SLE [64]. This study also found that the odds ratios
(ORs) for the development of SLE among individuals with
the T/T and I/T genotypes versus the I/I genotype were
2.3 and 1.1, respectively. A further comparison of genotype
frequencies with patient clinical data revealed that FCGR2B
polymorphismsstrongly associated with lupus nephritis (P =
0.01). This amino acid is in the transmembrane domain
of FcγRIIb, and the polymorphism reduces the signalling
capability of FcγRIIb due to its exclusion from lipid rafts
[75]. Thus balanced signalling through activatory and
inhibitory FcγRs regulates the activity of various cells in
the immune system and genetic evidence in both mice and
humans strongly supports the role of this receptor family in
preventing the development of autoimmunity.
2.3. CD11b/ITGAM. ITGAM encodes integrin alpha-M
(also commonly known as CD11b or complement receptor
3), the alpha chain of αMβ2 integrin which binds the cleavage
fragment of complement component C3b, an opsonin and
facilitates uptake of C3b-coated particles/pathogens into
phagocytic cells (reviewed in [76]). Genetic association of
ITGAM with SLE was found independently in 2 European
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GWAS [77, 78], with a non-synonomous functional variant
being identified in a subsequent study [79]. Functionally
this variant encodes an arginine to histine mutation at
amino acid 77 which alters both the structure and function
of integrin αM, thus reducing its ability to clear immune
complexes [80].
3. Toll-Like Receptor Signalling and
IFN Induction in SLE
Our increased awareness of the role played by cells of the
innate immune system in disease has stemmed from the
discovery of families of innate immune receptors, such as
the TLRs, which have evolved to recognise and discriminate
between different classes of pathogenesis reviewed in [81].
A link between antiviral pathogen recognition receptors and
SLE is now well established, thus giving credence perhaps
to the long-held view point that viral infection plays an
important role in either the etiology of SLE or in driving
flares in affected individuals [82]. With respect to SLE,
receptors that can recognise viral nucleic acids, such as the
endosomally located antiviral TLRs (TLR3, 7/8, and 9) [9–
11] the intracellular RIG-I-like receptors (RLRs) [83] and
AIM2-like receptors (ALRs) receptor families [84], have
been implicated in SLE. There now exists strong genetic
and functional evidence that RNA/DNA immune-complexes
found in lupus patients can drive IFN-α production through
the activation of TLR7 or TLR9 [85], respectively, indicating
that TLR7/9 activation may be an important primary trigger
for the generation of autoimmune disease (reviewed in
[5, 86]). Plasmacytoid dendritic cells have been identified
as the primary interferon-producing cells [87], however
immature monocytes have also been demonstrated to pro-
duce significant levels of IFN-α in a mouse model of
lupus and also in human SLE monocytes in response to
immune complex activation [88, 89]. In addition to the viral
TLRs themselves playing a role in the pathogenesis of this
condition, downstream signalling components of these and
their products may also contribute to the progression of
this condition. Firstly, it is well documented that roughly
half of all SLE patients overexpress IFN-α, thus giving
rise to changes of gene expression that can be detected in
peripheral blood monocytes, termed the IFN gene signature
[90–93]. More recently, the activity and expression of certain
members of the IRF family of transcription factors which
regulate IFN production and mediate its effects, specifically
IRF3 and IRF5, have been shown to be enhanced in SLE
monocytes, resulting in increased expression of a subset
of IRF-dependent genes [89, 94, 95]. For example, recent
studies have shown that the levels of IRF3 bound to the
promoter of a key pathogenic cytokine in SLE, IL-23, are
enhanced in monocytes from SLE patients, thus resulting
in increased basal production of this cytokine in SLE
monocytes [95]. Likewise, monocytes from SLE patients
present increased basal levels of nuclear IRF5 thus potentially
contributing to enhanced production of the cytokines IFN-
α, TNF-α, and IL-6 [96]. Thus not only are the triggers for
activating SLE monocytes or macrophages in abundance due
to impaired apoptotic cell clearance but also key downstream
transcription factors such as the IRF family appear to be
hyperresponsive in SLE monocytes [96], a finding inspired
by genetic evidence linking IRF5 to disease [97].
3.1. Genetic Association of Antiviral Toll-Like Receptors TLR7
and TLR9 with SLE. With respect to the initial recognition
of self-RNA and self-DNA by the antiviral TLRs, there
have been several genetic studies in both human and
murine models that further implicate these receptors in the
pathogenesis of this condition in particular TLRs 7 and 9
[25–27, 88–96, 98–102].
3.1.1. Toll Like Receptor 7 (TLR7). Mice lacking the TLR7
gene (located at Xp22.2) exhibit ameliorated disease,
decreased lymphocyte activation and a marked reduction
in the levels of RNA-containing antigens [98]. Interest-
ingly, BBXSB/MpJ (BXSB) mice bearing the Yaa gene (Y
chromosome-linked autoimmune acceleration gene) spon-
taneously develop a lupus-like autoimmunity, with males
being affected much earlier and to a greater extent than
their female counterparts. These Yaa containing mice were
found to have increased expression of TLR7 due to the
translocation of approximately 17 genes, including TLR7,
onto the pseudoautosomal region of the Y chromosome [99,
100]. Deane et al. (2007) demonstrated that this duplication
of the TLR7 gene and as a result, increased TLR7 expression,
promoted the production of RNA-containing autoantibodies
and development of lupus nephritis [101]. Although murine
studies have indicated associations between TLR7 gene
variations and SLE, there is controversy regarding human
association studies. Using candidate gene approaches, Shen
et al. (2010) investigated a role for TLR7 in SLE in Eastern
Asian populations in which they identified a functional
polymorphism in 3′ UTR of the TLR7 gene. This common
variant (rs3853839G/C) was found to be robustly associated
with SLE (P = 0.016), with a stronger effect seen in male
subjects compared to their female counterparts [25]. The
elevated levels of TLR7 transcripts and as a result, the
enhanced IFN signature in patients with the G-allele of
this single nucleotide polymorphism (SNP), have supported
a functional role for this polymorphism in SLE. However
when this SNP was studied in a non-Asian population, there
was no evidence for this SNP as a risk factor for SLE in
males with only females of non-Asian descent showing this
association [102]. Following on from this multicentre study,
Kawasaki et al. (2011), observed two additional variants
located within the intron (rs179019A/C and rs179010T/C)
that were also associated with SLE in a Japanese cohort
(P = 0.016 and 0.018, resp.) thus further supporting the
role of TLR7 as a risk factor for the development of this
autoimmune condition [26]. Further studies into TLR7
polymorphisms in a Brazilian population also suggested the
TLR7 SNP rs179008A/T as an SLE susceptibility factor in
women of European descent (P = 0.020); however, this was
not replicated in a Spanish population [27, 103]. Moreover
an additional study into the role of copy number variants
of TLR7 in SLE identified that increased TLR7 copy number
was also a risk factor for the onset of juvenile SLE [104].
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3.1.2. Toll-Like Receptor 9 (TLR9). In addition to enhanced
TLR7 expression, TLR9 has also been demonstrated to be
upregulated in SLE B cells [105], further implicating a
role for these viral TLRs in B cell tolerance and as result
in the progression of SLE. In murine models, a role for
TLR9 in disease susceptibility has also been examined with
varying results. Christensen et al. (2005) demonstrated that
TLR9 knockout mice crossed with lupus-prone mice exhibit
decreased levels of anti-DNA antibodies implicating this
gene as important in the progression of this condition [11].
However, in contrast the genetic ablation study carried out
by Wu and Peng investigating the role of TLR9 in SLE,
demonstrated that MRL mice lacking TLR9 developed more
severe lupus than MRL controls, demonstrating a protective
role for this gene in the pathogenesis of this condition
[106]. Although numerous SNPs have been identified in the
TLR9 locus (chromosome 3p21.3), which falls into the SLE
susceptibility region, there is very little correlation between
these variants and the onset of SLE and again this is an
area of major controversy within the literature. A number
of these common SNPs (rs187084, rs5743836, rs352139,
and rs352140) were investigated in a Hong Kong Chinese
population [107], however although overrepresented in SLE
showed no significant association. When the rs5743836
SNP was further analysed in Caucasian American individ-
uals, again no functional association was identified with
this polymorphism [108]. In contrast, studies in Brazilian
patients replicated these results reporting this SNP as an
SLE susceptibility factor (P = 0.045) [27]. Consistent with
results seen by Tao et al. investigating TLR9, the exonic
region rs352139A/G SNP has been mildly associated with
SLE (P = 0.040), with genetic analysis in a Japanese
population indicating that carrying the G allele of this
polymorphism predisposes individuals to an increased risk
of SLE through the downregulation of TLR9 expression levels
in reporter gene assays [28]. In addition to this, when the
rs352140C/T in exon 2, was examined using a family-based
association in China it was also reported that this SNP was
also mildly associated with disease susceptibility (P = 0.045)
[29].
The divergent roles played by TLR7 and 9 in autoimmu-
nity are reflected in the variation seen in TLR7/9 polymor-
phisms and their subsequent effect on disease progression.
TLR7 polymorphisms appear to increase expression of this
gene leading to the enhanced recognition of autoantibodies
culminating in an enhanced IFN signature thus predisposing
these individuals to SLE [99]. On the other hand, TLR9
polymorphism associations, whilst controversial, particu-
larly with respect to the different genetic backgrounds
of the populations examined, suggest that TLR9 SNPs
downregulate its expression and in doing so increase disease
susceptibility [107]. Although the exact mechanism for this
is not yet known, it has been suggested that lower levels of
TLR9 expression lead to defective T regulatory cell activation
which contributes to the decrease in number and immuno-
suppressive function of these cells in the MRL model of
murine lupus [106]. Despite some controversy surrounding
individual TLR7/9 SNPs in SLE, there is a growing body
of evidence emerging to suggest that polymorphisms in
these receptors play a role in genetic predisposition to this
condition.
3.2. TLR Signalling Components. Activation of TLR7 and
TLR9 by self nucleic acids and immune complexes has been
demonstrated to contribute to the pathogenic production
of IFN-α and proinflammatory cytokines such as TNF-α,
IL-6 and IL-12 [109, 110]. A number of genes involved in
type I IFN production and signalling have been linked to
SLE [111–113]. Proteins directly activated downstream of
TLR7 and TLR9, such as TRAF6 [12] and the IRF family
of transcription factors [13], have known genetic association
with SLE. In addition, proteins that negatively regulate TLR-
induced activation of transcription factors IRF7 and NF-κB
such as A20, have also been shown to contribute to lupus
susceptibility in a combination of either GWAS or candidate
gene approaches [31, 33, 114].
3.2.1. TRAF6. TNF-receptor-associated factor 6 (TRAF6)
plays an important role in many signalling pathways that
are important for immune regulation. TRAF6 was firstly
identified in 1996 as a signal transducer in the NF-κB path-
way which associates with interleukin-1 receptor-associated
kinase (IRAK) [115]. Recent studies have suggested that
polymorphisms within TRAF6 may be associated with the
development of SLE, with SNPs in the TRAF6 gene giving
nominal signals of association with SLE in an extended
family Swedish cohort [116]. A more recent study showed a
direct correlation between TRAF6 SNPs and SLE, supporting
the notion that TRAF6 is potentially involved in the patho-
genesis of autoimmune conditions [12]. In this study, fifteen
SNPs across TRAF6 were evaluated in 7,490 SLE patients and
6,780 control subjects from different ancestries. Evidence of
associations was detected in multiple SNPs, with rs5030437
and rs4755453 showing the strongest association [12].
3.2.2. TREX1. TREX1 encodes the most abundant 3′-5′
exonuclease inmammalian cells and has also been implicated
in the cell death process, recognising and degrading genomic
DNA and endogenous retroviral elements to minimize
potential immune activation by persistent immunostimu-
latory DNA in the cytoplasm [117] (reviewed in [118]).
Various genetic studies have identified a number of loss-of-
function mutations in TREX1 that give rise to SLE, famil-
ial chilblain lupus (FCL), or Aicardi-Gautieres syndrome
(AGS), an autoimmune disorder that presents as early onset
encephalopathy resulting in severe intellectual and physical
handicap [119–122]. Functional studies into these loss-of-
function mutants of TREX1 demonstrate that they result
in enhanced levels of immunostimulatory DNA resulting in
enahnced type I IFN production. For example, TREX1D18N
and TREX1D200N heterozygous mutants have been iden-
tified in FCL and AGS, respectively, and functionally are
completely deficient at degrading dsDNA and demonstrate
a lower rate of degradation of ssDNA than wild-type
TREX1. The TREX1R114H homozygous mutation identified
in AGS patients is found as a heterozygous mutation in
SLE. As a homodimer TREX1R114H shows defects in its
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ability to degrade both ds- and ss-DNA, indicating that
loss of function of TREX1 results in enhanced levels of
immunostimulatory DNA which in turn results in enhanced
levels of type I IFNs observed in both SLE and AGS
[123, 124]. These findings clearly implicate TREX1 as an
important endogenous DNA sensor that works to prevent
inappropriate immune activation.
3.2.3. IRF5. Association of IRF5 genetic variants with SLE
susceptibility has been first reported following a screening
of genes involved in type I IFN production and response
in Swedish, Icelandic, and Finnish patients with SLE [13].
Since then, the evidence of a link between IRF5 and SLE has
been replicated in a number of case-control linkage studies
in different populations [125–128] and GWAS analyses
(reviewed in [129]). Association of IRF5 with SLE is com-
plex, and a number of genetic studies have allowed defining
risk, neutral, and protective haplotypes. Initially, 3 common
polymorphisms in the IRF5 gene (SNPs rs2004640 in the 5′
UTR and rs10954213 in the 3′ UTR and a 30 nucleotides
insertion in exon 6) [97] were proposed to alter the function
or levels of IRF5 mRNA and proteins, thus explaining the
association of risk alleles of these polymorphisms with SLE.
A subsequent study by Sigurdsson et al. [130] identified two
IRF5 polymorphisms independently and strongly associated
with SLE: a 5 bp CGGGG insertion located 64 base pairs
upstream of IRF5 exon 1a (P = 4.6 × 10−9) and a SNP
(rs10488631) downstream of the IRF5 gene (P = 9.4×10−10).
The presence of the insertion creates an additional binding
site for the transcription factor Sp1, leading to increased
transcription of IRF5 [130]. Interestingly, the CGGGG inser-
tion is in linkage disequilibrium with SNPs rs2004640 and
rs10954213, thus accounting for the association previously
observed between these two SNPs and SLE. Interestingly,
the CGGGG insertion in IRF5 promoter has been associ-
ated with a number of autoimmune conditions, such as
primary Sjo¨gren’s syndrome [131], Multiple sclerosis [132],
inflammatory bowel disease and Crohn’s disease [133], while
the haplotype tagged by rs10488631 seems to be specific
in conferring SLE susceptibility [130]. A recent study by
Hedl and Abraham [134] has found that monocyte-derived
cells from healthy individuals carrying the risk alleles of
SNP rs2004640 and the CGGGG insertion secreted elevated
levels of proinflammatory cytokines following stimulation
with Nod2 and TLRs ligands, thus suggesting a correlation
between IRF5 genetic variants and transcriptional activity. In
keeping with this, it has been shown that patients carrying
IRF5-risk haplotypes have increased levels of circulating
IFNα in the serum compared to patients carrying neutral
or protective haplotypes. Of note, such correlation was
observed only in patients positive for either anti-dsDNA
or anti-RBP autoantibodies [135], and the study was sub
sequentially expanded to show that different classes of
autoantibodies are linked to different IRF5 haplotypes. Since
autoantibodies can deliver self nucleic acids to endosomal
TLRs [136], thus activating IRF5, the authors proposed that
distinct classes of autoantibodies could activate specific IRF5
variants, leading to dysregulation of IFNα production and
increased transcription of interferon-stimulated genes [137].
3.2.4. IRF7. IRF7 is considered the master regulator of
IFNα production downstream the antiviral TLRs [138], and
polymorphisms in this gene could therefore be an ideal
candidate for genetic susceptibility to SLE. Together with
IRF5, IRF7 has been shown to be necessary for murine
DCs-mediated production of IL-6 and IFNα induced by
immune complexes isolated from SLE patients’ sera, again
indicating a central role for these transcription factors in the
disease context [85]. SNPs in the genetic region spanning
the IRF7 gene (adjacent to the PHRF1 locus, also known as
KIAA1542) have been identified, and different groups have
attempted to associate common genetic variants at this site
with SLE susceptibility. A GWAS in women affected by SLE
has found a correlation between SNP rs4963128 inKIAA1542
and lupus (P = 3 × 10−10). Since this SNP is in strong
linkage disequilibrium with SNP rs702966 located within
0.6 kb of IRF7, it was thought that variability at this site could
represent the signal deriving from IRF7 [78]. Association of
these two SNPs with lupus susceptibility has been replicated
in populations of different ancestries by Salloum et al. [139].
Interestingly, this study demonstrated a correlation between
the risk alleles of these SNPs and increased levels of IFNα,
but only in patients with autoantibodies. Similar to what
has been suggested for IRF5, potential autoantibodies might
cooperate with SLE-associated IRF7 variants through TLR
activation, resulting in increased type I IFN production
which leads to breaking of tolerance and the onset of disease.
In keeping with this, SNP rs4963128 was correlated with
nephritis and anti-Ro/anti-La autoantibodies in a Chinese
population, although no association of this SNP with lupus
susceptibility was observed in this genetic background [39].
To date, the only known functional polymorphism in IRF7
is the nonsynonymous SNP rs1131665 which encodes a
protein carrying a Q to R mutation at position 412 [30]. This
variant has been shown to be associated with SLE patients of
Asian and European American ancestry (P = 6.18 × 10−6),
and functional analysis of the mutated protein revealed its
enhanced transcriptional activation of an ISRE-dependent
promoter. This is in keeping with the hypothesis that SLE-
associated IRF7 polymorphisms may lead to the expression
of proteins with increased activity downstream of the TLRs,
thus leading to overproduction of type I IFN characteristic of
the disease.
3.2.5. TNFAIP3. Tumour necrosis factor α-induced protein
3 (TNFAIP3), the gene product of which is the ubiquitin
editing protein A20, is an essential negative regulator of path-
ways regulating NF-κB [140–142]. Recently TNFAIP3/A20
has been shown to interact with and negatively regulate IRF7,
thus potentially explaining its molecular involvement in SLE
[143]. Polymorphisms within the TNFAIP3 genomic locus,
located at 6q23, have been associated with autoimmune
disorders such as SLE [31, 35, 114, 144, 145] in Caucasian,
Asian and Japanese populations. In particular, three inde-
pendent SNPs in the TNFAIP3 gene (rs13192841, rs2230926
and rs6922466) are thought to be associated with SLE
patients of European ancestry [31]. More recently the results
of a meta-analysis of genome-wide association scans and
replication in independent sets for TNFAIP3 polymorphism
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and SLE showed another TNFAIP3 SNP (rs2230926) to have
an association with SLE [32]. This sample set contained
12,416 subjects with SLE from multiple ethnic groups and
so suggested that this particular SNP may be conserved
throughout diverse populations. In order to fully characterise
the TNFAIP3 risk haplotype, fine mapping and genomic
resequencing in ethnically diverse populations were carried
out [146]. Results suggested a TT>A variant to be the
most likely functional polymorphism responsible for the
association between TNFAIP3 and SLE in subjects of both
European and Korean ancestry [146]. This variant displayed
a reduced binding avidity for NF-κB subunits. In addition,
the haplotype carrying this variant resulted in reduced
TNFAIP3 mRNA and A20 protein expression [146]. These
findings underscore the crucial role of NF-κB regulation in
the pathogenesis of SLE.
The TNFAIP3 interacting protein 1, (TNIP1), also
known as ABIN1, interacts with TNFAIP3/A20 and pro-
motes inhibition of NF-κB activity [147, 148]. TNIP1 has
also been shown to be associated with SLE in a wide range
of ethnic groups. Two individual GWAS revealed association
of TNIP1 intronic SNPs, rs7708392, and rs10036748, with
SLE in both Caucasian and Chinese populations [35, 36].
Subsequently a study was carried out in a Japanese popu-
lation which confirmed the association of TNIP1 rs7708392
with SLE [148]. Interestingly in this study, this SNP showed
a tendency of stronger association with SLE patients with
renal disorder than in all SLE patients. Overall these studies
highlight the important role that both TNFAIP3 and TNIP1
play in genetic predisposition to autoimmune disorders such
as SLE.
3.3. Interferon Signalling Components. Serum levels of type I
IFN correlate with disease activity and clinical manifestation
[14], and interestingly lupus-like disorders can be induced
during type I IFN therapy, again highlighting the pivotal
role of these cytokines in disease development [149, 150].
Secreted type I IFN can then signal through the type I IFN
receptor and kinases; tyrosine kinase 2 (TYK2) and janus
kinase 1 (JAK1) [151]. Activation of the type I IFN receptor
triggers phosphorylation of the transcription factors signal
transducer and activator of transcription 1 and 2 (STAT1
and STAT2) and assembly of the interferon stimulated gene
factor 3 (ISGF3) complex, which then translocates to the
nucleus where it regulates production of IFN-stimulated
genes necessary to establish the antiviral state (Figure 2)
[152]. Polymorphisms in genes such as TYK2 and STAT4,
involved in signalling downstream of the type I IFN receptor
and a number of other cytokines, have been identified that
might instead alter responses to type I IFN in SLE [37, 38,
41, 42, 153–159].
3.3.1. STAT4. STAT4, the signal transducer and activator
of transcription 4 gene, encodes a transcription factor that
mediates the effect of several cytokines, including IL-12, the
type I interferons, and IL-23 in T cells and monocytes [153].
Thus, STAT4 has a role in T-cell differentiation, monocyte
activation, and IFN-γ production. STAT4 was confirmed in
2003 by Jacob et al. to play a key role in the pathogenesis
of a lupus-like disease in mice [154]. They showed that
loss of STAT4 led to accelerated renal disease and increased
mortality. A number of genetic studies have identified
STAT4 SNPs with links to SLE in Caucasian populations
for example, rs7582694 [37], rs7601754 and rs7574865 [38],
and rs7582694 [155], in addition to rs7574865 and SLE in a
Northern Han Chinese population [39]. Using transmission
disequilibrium test analysis the rs7582694 SNP was found to
have a strong association with SLE (P = 0.002, OR = 2.57) in
a Finnish family cohort [37]. Using meta-analysis the SNPs
rs7601754 and rs7574865 were found to have a significant
association with SLE (P < 0.001) in populations of European
and African origin [38]. Sigurdsson et al. (2008), in using
a candidate gene study, also identified the SNP rs758294 as
part of a common-risk haplotype for SLE (P = 1.7 × 10−5)
in Swedish patients with SLE [155]. Li et al. (2011), using a
candidate gene study in a Northern Han Chinese population,
found a strong association between the SNP rs7574865 and
SLE (P = 1.57 × 10−6) [39]. These SNPs are located within
introns and are therefore suggested to play a role in the
regulation of the expression level or splicing of the gene
[155].
3.3.2. TYK2. TYK2 binds to the type I IFN receptor
(IFNAR), thus initiating the JAK-STAT signalling cascade,
culminating in the transcription of further type I IFN and
IFN inducible genes [156]. A number of SNPs in TYK2
have been recently reported to be associated with SLE in
Caucasian populations, namely, rs280519, rs2304256, and
rs12720270 [13, 41, 42]. The TYK2 SNP rs280519 was found
to be associated with SLE across a genome-wide association
combined between a UK and Swedish cohort (P = 3.88 ×
10−8) [41]. The TYK2 SNP rs2304256, was found to be
associated with SLE in a Scandinavian cohort (P = 5.6 ×
10−6) [13], but not associated with SLE in a UK cohort [42],
however this same UK study also found another TYK2 SNP,
rs12720270, associated with SLE that was not found within
the Scandinavian cohort (P = 0.004). This SNP, rs12720270,
however, was not found to be associated with SLE by
Lee et al., when conducting meta-analysis on associations
between SLE susceptibility and this SNP of TYK2 [157].
The rs2304256 is located in exon 8, and the rare A allele of
the SNP causes a substitution of Val to Phe at residue 362
in the Jak-homology 4 (JH4) region of TYK2. This region
is important for the interaction of TYK2 with IFNAR1, its
function [158], as well as for maintaining the expression of
IFNAR1 on the cell surface [159], suggesting that this SNP
may reduce the function of TYK2 and thus susceptibility to
autoimmune diseases.
4. Conclusion
Evidence from GWAS and candidate gene approaches have
uncovered an array of genes that have functional con-
sequences for how monocytes and macrophages respond
to immune challenge during the course of disease. Many
of these genes regulate either phagocytic, TLR, or IFN
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Figure 2: TLR induced IFN production and signalling in SLE. A brief outline of the signalling pathways involved in the production of type
I IFNs in SLE. Activation of the transcription factors downstream of endosomal TLRs and Fc Receptors leads to the production of type I
IFNs. These IFNs are secreted and further detected by IFN receptors, further activating interferon stimulated genes.
systems—three areas now well recognised to contribute to
disease pathology. And as we become increasingly aware
of the growing role of macrophages in disease pathology,
it is interesting to note that cross-regulation of dendritic
cells, the other major innate immune cell player in SLE
pathology, by macrophages has an important role in driving
disease. For example, C1q deficiency not only results in
reduced uptake of immune complexes by macrophages and
dendritic cells but it also is a negative regulator of IFN
production by dendritic cells, thus its loss negatively impacts
both macrophage and dendritic cell function in the context
of disease pathology—exacerbating type I IFN production
and contributing to a vicious cycle of reduced immune
tolerance [160]. With respect to many of the genes discussed
above, the functional relevance of their genetic variation
has yet to be determined—do they contribute to pathogenic
splice variants, altered transcript, or protein stability, or
indeed introduce functional mutations that contribute to
either over- or underactivation of the gene product? For
others however, such as Trex1, not only is the molecular
involvement of these variants in disease known, but research
into their involvement in disease has uncovered novel
functions for these proteins in innate immunity. However,
where genetic associations uncovered have yet to conclusively
demonstrate functional relevance for immune function in
the context of SLE, we must be aware that many of the SNPs
uncovered in SLE susceptibility regions may in fact have
no true role in genetic susceptibility but instead, through
linkage disequilibrium, act as a tag or marker for the real
susceptibility gene. As researchers continue unravelling the
functionality of genetic variability within SLE and translating
these findings functionally to their contribution to immune
dysregulation in SLE then we can undoubtedly expect this
knowledge to contribute to greater insight into the molecular
workings of disease. Already there are indications that certain
SNPs appear to stratify with different disease manifestations
and autoantibody profiles in SLE [161, 162], indicating the
utility of screening to better inform and manage disease.
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